1,3,5-triacryloylhexahydrotriazine (TAH) is a **monomeric crosslinking agent** with the molecular formula C12H15N3O6. It is a white, crystalline powder that is soluble in organic solvents such as acetone and chloroform.
**Here's why TAH is important in research:**
* **Polymer chemistry:** TAH plays a significant role in polymer synthesis due to its unique structure. It contains three acryloyl groups that can react with various monomers, leading to the formation of crosslinked polymers. These crosslinked polymers exhibit enhanced properties such as improved mechanical strength, thermal stability, and resistance to chemicals.
* **Biomedical applications:** TAH has potential applications in biomedical engineering, particularly in the field of biomaterials and tissue engineering. Its ability to crosslink with biocompatible materials can create hydrogels and scaffolds with controlled porosity and degradation properties, making them suitable for cell growth and tissue regeneration.
* **Dental applications:** TAH is used in dental materials, specifically in composite resins. Its crosslinking ability strengthens the resin matrix, improving its durability and resistance to wear.
* **Other applications:** TAH finds applications in various other fields, such as coatings, adhesives, and optical materials, due to its ability to modify the properties of materials through crosslinking.
**Research focus areas:**
* **Synthesis and characterization:** Researchers investigate various methods to synthesize TAH with controlled purity and molecular weight. The characterization of TAH includes its structural analysis, thermal properties, and reactivity.
* **Polymerization studies:** TAH is studied in various polymerization reactions, including free radical polymerization and controlled radical polymerization, to understand the mechanism of crosslinking and its influence on the properties of the resulting polymers.
* **Biocompatibility and bioactivity:** TAH is investigated for its biocompatibility with living cells and tissues. Researchers explore its potential applications in tissue engineering, drug delivery, and wound healing.
* **Applications in specific fields:** TAH is investigated for its use in specific fields, such as dental materials, coatings, and optical materials, to optimize its performance and explore its potential benefits.
In summary, 1,3,5-triacryloylhexahydrotriazine is a versatile crosslinking agent with promising applications in various fields, especially polymer science and biomedical engineering. Ongoing research focuses on understanding its properties, developing new applications, and optimizing its performance for specific needs.
1,3,5-triacryloylhexahydrotriazine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 70397 |
| SCHEMBL ID | 214239 |
| MeSH ID | M0141753 |
| Synonym |
|---|
| 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)trisprop-2-en-1-one |
| STK696230 |
| tris(n-acryloyl)hexahydrotriazine |
| ek-8694 |
| 1,5-triacryloyl-s-triazine |
| 959-52-4 |
| hexahydro-1,5-triacryloyl-s-triazine |
| fixierer p |
| tris(acryloyl)hexahydro-s-triazine |
| nsc-8185 |
| 1,5-triacryloylhexahydrotriazine |
| 1,5-triacryloylhexahydro-1,3,5-triazine |
| triacryloylhexahydro-s-triazine |
| triacrylformal |
| triacryloylhexahydrotriazine |
| hexahydro-1,5-triacryloyltriazine |
| s-triazine,3,5-triacryloylhexahydro- |
| triacryloylperhydrotriazine |
| 1,5-triacryloylhexahydro-s-triazine |
| 1,5-triacryloyltrimethylenetriamine |
| 1,5-tris(acryloyl)hexahydro-s-triazine |
| tri(n-acryloyl)hexahydrotriazine |
| 1,5-triazine, hexahydro-1,3,5-tris(1-oxo-2-propenyl)- |
| nsc8185 |
| nsc63839 |
| nsc-63839 |
| 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one |
| 1,3,5-triacryloyl-s-triazine |
| 1,3, 5-triacryloylhexahydro-1,3,5-triazine |
| 1,3, 5-tris(acryloyl)hexahydro-s-triazine |
| 1,3,5-triacryloylhexahydro-s-triazine |
| 1,3, 5-triacryloyltrimethylenetriamine |
| 1,3,5-triazine, hexahydro-1,3, 5-tris(1-oxo-2-propenyl)- |
| hexahydro-1,3, 5-triacryloyltriazine |
| 1,3, 5-triacryloylhexahydrotriazine |
| 1,3,5-triacryloyl-1,3,5-triazinane |
| hexahydro-1,3,5-triacryloyl-s-triazine |
| s-triazine, 1,3,5-triacryloylhexahydro- |
| 1,3,5-triacryloylhexahydro-1,3,5-triazine, 98% |
| ai3-50778 |
| brn 0225908 |
| hexahydro-1,3,5-tris(1-oxo-2-propenyl)-1,3,5-triazine |
| nsc 63839 |
| hexahydro-1,3,5-triacryloyltriazine |
| s-triazine, hexahydro-1,3,5-triacryloyl- |
| 1,3,5-tris(acryloyl)hexahydro-s-triazine |
| 1,3,5-triacryloylhexahydrotriazine |
| hexahydro-1,3,5-tris(1-oxoallyl)-1,3,5-triazine |
| 1,3,5-triacryloyltrimethylenetriamine |
| nsc 8185 |
| 1,3,5-triacryloylhexahydro-1,3,5-triazine |
| 1,3,5-triazine, hexahydro-1,3,5-tris(1-oxo-2-propenyl)- |
| einecs 213-501-6 |
| NCIOPEN2_002638 |
| SR-01000089822-2 |
| HMS1667F02 |
| T1000 |
| 2-propen-1-one, 1,1',1''-(1,3,5-triazine-1,3,5(2h,4h,6h)-triyl)tris- |
| ec 213-501-6 |
| p69a1s76rb , |
| unii-p69a1s76rb |
| 4-26-00-00012 (beilstein handbook reference) |
| triacryloylhexa-1,3,5-hydrotriazine |
| CCG-51428 |
| AKOS005524478 |
| 1-(3,5-diacryloyl-1,3,5-triazinan-1-yl)-2-propen-1-one |
| 1-[3,5-bis(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one |
| SCHEMBL214239 |
| 1,3,5-triacryloylaminohexahydro-s-triazine |
| hexahydrotris(acryloyl)-s-triazine |
| 1,3,5-triacryoyl-1,3,5-triazinane |
| fixing agent p |
| triacryloyl-hexahydro-s-triazine, 1,3,5- |
| 1,3,5-triacryoyl-1,3,5-triazinane (tata) |
| DTXSID8052645 |
| FYBFGAFWCBMEDG-UHFFFAOYSA-N |
| 1,3,5-triacryloyl-1,3,5-triazinane # |
| sr-01000089822 |
| SR-01000089822-1 |
| mfcd00035738 |
| 1,3,5-triacryloyl-hexahydro-s-triazine |
| 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one |
| du 801;nsc 8185;fixierer p |
| AMY12551 |
| E78999 |
| Q27286283 |
| BS-43826 |
| PD194525 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "TAHT (1,3,5-triacryloylhexahydro-s-triazine), a reactive chemical coupling agent, was highly toxic following a single peroral dose of an aqueous suspension (10% w/v) to Wistar rats, or following application of TAHT in dichloromethane (DCM) solution (10% w/v) to covered skin of New Zealand rabbits." | ( Studies on the acute toxicity primary irritancy and genotoxic potential of 1,3,5-triacryloylhexahydro-s-triazine (TAHT). Ballantyne, B; Guzzie, PJ; Hengler, WC; Myers, RC; Slesinski, RS, 1986) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, 24-h exposures to TAHT on covered skin produced erythema, edema, ecchymoses, scabs, and death depending upon dosage and vehicle." | ( Studies on the acute toxicity primary irritancy and genotoxic potential of 1,3,5-triacryloylhexahydro-s-triazine (TAHT). Ballantyne, B; Guzzie, PJ; Hengler, WC; Myers, RC; Slesinski, RS, 1986) | 0.27 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.32) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||